JNJ-42160443

DRUG5 trials

Sponsors

Janssen Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

ArthralgiaCystitisCystitis, InterstitialJoint PainMononeuropathiesNeuralgiaNeuralgia, PostherpeticOsteoarthritis

Phase 2

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

CompletedNCT00929188

Janssen Research & Development, LLCPain, Burning, Pain, Crushing, Pain, Migratory +2

Start: 2009-10-31End: 2015-01-31Updated: 2016-01-22

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

TerminatedNCT00964990

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Mononeuropathies, Neuralgia, Neuralgia, Postherpetic +1

Start: 2009-09-30End: 2011-07-31Updated: 2016-05-02

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

TerminatedNCT00973141

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Arthralgia, Joint Pain, Osteoarthritis +3

Start: 2009-09-16End: 2011-06-30Updated: 2020-03-11

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

TerminatedNCT01060254

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Cystitis, Cystitis, Interstitial, Urinary Bladder Diseases +1

Start: 2010-04-06End: 2011-06-24Updated: 2021-10-18

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

TerminatedNCT01094262

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Arthralgia, Joint Pain, Osteoarthritis +2

Start: 2010-04-20End: 2011-07-01Updated: 2020-03-11

Related Papers

Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study.

2017-01-0519 citations

Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial

International Journal of Clinical Practice2016-05-3036 citations